Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
On Tuesday, JMP Securities maintained a positive outlook on Cytokinetics (NASDAQ:CYTK), with analyst Jason Butler reiterating a Market Outperform rating and a $78.00 price target. According to InvestingPro data, analyst targets for CYTK range from $41 to $120, with the stock currently trading near $34, significantly below its 52-week high of $68.44. Butler’s confidence in the biopharmaceutical company remains steadfast despite recent discussions surrounding the Risk Evaluation and Mitigation Strategy (REMS) for aficamten, a drug developed by Cytokinetics.
Cytokinetics recently announced its first-quarter financial results for 2025 and provided updates on its business operations. A key topic during the earnings call was the U.S. Food and Drug Administration’s (FDA) decision to extend the Prescription Drug User Fee Act (PDUFA) date for aficamten by three months to December 26, 2025. The extension is to allow the FDA more time to review the New Drug Application (NDA) for aficamten, which was submitted without a REMS plan.
Butler noted that while there are varying opinions on the strategy of submitting the NDA without a REMS, JMP Securities’ view of aficamten as a leading drug in its category remains unaltered. The firm anticipates that aficamten will receive FDA approval with a differentiated REMS, which would likely include less stringent echocardiogram (ECHO) monitoring and no drug-drug interactions (DDIs), setting it apart from competitors like CAMZYOS. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 6.17, providing financial flexibility during this crucial regulatory phase.
The analyst also mentioned that the three-month delay in the PDUFA date is not seen as significant. Instead, JMP Securities views the recent decline in Cytokinetics’ stock price as an opportunity for investors to buy shares before the expected release of Phase 3 MAPLE-HCM trial results later this month. InvestingPro subscribers can access 10+ additional ProTips and comprehensive analysis about CYTK, including detailed insights about its financial health, valuation metrics, and growth prospects. The stock has experienced a significant 20.7% decline over the past week, now trading near its 52-week low.
Cytokinetics is focused on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. While the company posted impressive revenue growth of 145% in the last twelve months, investors should note that analysts don’t expect profitability this year, according to InvestingPro’s comprehensive analysis available in the Pro Research Report, which provides deep-dive analysis of 1,400+ top stocks.
In other recent news, Cytokinetics, Inc. reported a net loss of $161.4 million for the first quarter of 2025, equating to $1.36 per share. The company’s revenue was $1.6 million, which fell short of the projected $3.6 million. Despite the earnings per share slightly surpassing the forecast of a $1.37 loss, the revenue miss highlights ongoing challenges. Cytokinetics is advancing its aficamten NDA for the treatment of obstructive hypertrophic cardiomyopathy (OHCM) and anticipates FDA approval by December 2025. The company also projects full-year GAAP operating expenses between $670 million and $710 million. Analyst discussions focused on the regulatory pathway for aficamten, with Cytokinetics clarifying its interactions with the FDA. The company remains focused on its pipeline, with significant R&D expenses reflecting its commitment to innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.